19 research outputs found
'Black Spots' and hyaline pleural plaques on the parietal pleura of 150 urban necropsy cases.
The absence of any direct connection between the lung and the parietal pleura raises questions about the mechanisms of pleural migration and retention of inhaled particles. It has been suggested that specific areas of parietal pleura absorb and retain inorganic particles from the pleural space, including carbon pigments and asbestos fibers, and could be starting points for pathologic changes induced by mineral fibers. These particle-collecting structures have been called "black spots." To study their distribution, macroscopic appearance, and possible relationship with pleural plaques, the parietal pleura of 150 consecutive necropsies of urban dwellers (mean age 67.7 +/- 12.9 years) were examined. The size and intensity of spots were scored and recorded on a computer scheme together with information of the presence of pleural plaques. Black spots were observed in 92.7% of the cases. They were mainly located in the lower costal and diaphragmatic zones and could correspond to the anatomic distribution of structures involved in pleural cavity clearance. Scores correlated with sex and age. There was no relationship between the predominant locations of black spots and hyaline pleural plaques.Journal ArticleResearch Support, Non-U.S. Gov'tinfo:eu-repo/semantics/publishe
T1126 Response and Remission At 18 Months of Certolizumab Pegol in Patients with Active Crohn's Disease Is Not Influenced By Rapidity and Magnitude of Induction: An Analysis of PRECISE 2 and 3
S1065 Predictors of Endoscopic Response and Remission in Patients with Active Crohn's Disease Treated with Certolizumab Pegol: A Logistic Regression Analysis of the Music Data
S1058 Certolizumab Pegol Improves Health-Related Quality of Life in Crohn's Disease Patients for Whom Infliximab Treatment Was Not Successful: Results from the WELCOME Study
Recommended from our members
494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study
Recommended from our members
Certolizumab Pegol Is Efficacious in Crohn始s Disease Patients Who Have Failed Infliximab Regardless of Concomitant Therapy or Reason for Failure聽1103
Recommended from our members
Efficacy of Certolizumab Pegol is Not Affected by Baseline Anti-infliximab Antibody Status in Patients with Crohn始s Disease with Secondary Infliximab Failure聽1217
Recommended from our members
Regain of Response and Remission by Dose Adjustment in Patients with Crohn始s Disease Who Responded to Certolizumab Pegol: Results from the WELCOME Study聽1214
494 Efficacy and Safety of Certolizumab Pegol in Patients with Active Crohn's Disease Who Previously Lost Response or Were Intolerant to Infliximab: Open-Label Induction Preliminary Results of the Welcome Study
Recommended from our members